Could a russian drug boost brain function in chronic ischemia?
NCT ID NCT06834490
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the drug Mexidol (given first as injections, then as pills) can improve thinking and memory in people with chronic cerebral ischemia, a condition where the brain doesn't get enough blood flow. 318 adults aged 40-90 with mild to moderate cognitive impairment took part. The main goal was to see if their scores on a cognitive test (MoCA) improved after treatment compared to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mexidol (ethylmethylhydroxypyridine succinate)
What this could lead to
If it works, this could offer a treatment option to slow cognitive decline in people with chronic cerebral ischemia.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The improvement in cognitive scores may be small or not clinically meaningful.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC CEREBRAL ISCHEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre for Neurology and Neurorehabilitation n.a. N. M. Madzhido, OOO "Neyromed Servis"
Tashkent, 100187, Uzbekistan
-
City Hospital No.40 of the Kurortny District
Sestroretsk, 197706, Russia
-
Federal State Budget Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education"
Moscow, 125445, Russia
-
Federal State Budget Educational Institution of Higher Education "Kazan State Medical University"
Kazan', 420012, Russia
-
Federal State Budget Military Educational Institution of Higher Education "Military Medical Academy n.a. S.M.Kirov"
Saint Petersburg, 194044, Russia
-
Federal State Budget Research Institution "Federal Research Center for Fundamental and Translational Medicine"
Novosibirsk, 630117, Russia
-
Federal State Budget Research Institution "Research Center of Neurology"
Moscow, 125367, Russia
-
Municipal Autonomous Healthcare Insitution of the Order of the Red Banner of Labour "City Clinical Hospital No.1"
Chelyabinsk, 454092, Russia
-
OOO "Centre for Evidence-Based Medicine"
Yaroslavl, 150000, Russia
-
Private Healthcare Institution "Clinical Hospital "RR-Medicine" of Voronezh
Voronezh, 394024, Russia
-
Regional Budget Healthcare Institution "Ivanovo Regional Clinical Hospital"
Ivanovo, 152040, Russia
-
State Budget Healthcare Institution of the Novosibirsk Region "City Hospital № 34"
Novosibirsk, 630054, Russia
-
State Budget Healthcare Institution of the Sverdlovsk Region "Sverdlovsk Regional Clinical Hospital No.1"
Yekaterinburg, 620102, Russia
-
State Budget Healthcare Institution of the Yaroslavl Region "Clinical Hospital No.2"
Yaroslavl, 150030, Russia